Assessing new therapeutic opportunities linked to TCR signalling in mature T-cell lymphomas with unmet need

有关患者肿瘤的特定分子和基因构成的知识为诊断和治疗决策提供了有价值的指导。这种方法被称为个性化或精准医学，已经认识到对患者、药物开发和医疗保健的好处。然而，将描述肿瘤遗传异常的信息与成功的新疗法联系起来，需要大量的研究工作。在这项提案中，我们概述了我们评估T细胞淋巴瘤新的潜在药物靶点的计划，在T细胞淋巴瘤中，患者目前的治疗结果仍然黯淡，而且最近的遗传学研究强调了可能与癌症发展有关的变化。我们将结合专业知识进行密切合作，我们认为这是必要的，以提供确凿的支持证据。这些专门知识包括长期参与特定形式的T细胞淋巴瘤发展的研究，以及广泛的专门知识和对潜在靶点的结构和机制的理解作出的贡献，这两方面都将促进药物开发的持续努力。这将汇集对分离蛋白质研究的深入见解、对实际患者肿瘤细胞的分析结果以及潜在药物的初步产生和表征，所有这些都使用了各自研究领域的最新方法进步。如果证实可行，新的治疗方案将具有更广泛的相关性，包括一些其他癌症类型、特定癌症的耐药性和一系列免疫疾病。

Knowledge about the specific molecular and genetic makeup of a patient's tumour provides valuable guide for diagnosis and for decisions about the treatment. This approach, described as personalized or precision medicine, has recognized benefits for patients, drug development and healthcare. However, linking information that describes genetic aberrations in tumours with successful new treatments requires considerable research effort. In this proposal we outline our plan to assess new potential drug targets in T-cell lymphomas where patient's outcome with current treatments remains bleak and where recent genetic studies highlighted changes that could be linked to cancer development. We will combine expertise in a close collabariton that we believe is necessary to provide definitive supporting evidence. This expertise covers long standing involvement in studies of the development of particular forms of T-cell lymphomas and an extensive expertise and contribution to structural and mechanistic understanding of potential targets which will both facilitate ongoing efforts in drug development. This will bring together in-depth insights from studies of isolated proteins, findings from the analysis of cells from actual patient's tumours and initial generation and characterization of potential drugs, all using the latest methodological advances in respective research areas. If confirmed as feasible, the new treatment options will have a wider relevance, including some other cancer types, drug-resistance in specific cancers and a range of immune disorders.